Clinical Trial Search

Primary: Dose-limiting Toxicity of Gemcitabine Due to Non-hematologic Toxicity — 0; 3 participants

Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival

Primary: Transplant Related Mortality Rate — 1; 6 Participants

Primary: Progression-free Survival (PFS) — 18 participants

Primary: Progression-free Survival (PFS) — 89.7; 50 percentage of participants

Primary: Failure-free Survival at 5 Years — 0.74; 0.71 Proportion of patients — p=0.32

Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970

Primary: Event-free Survival — 0.89; 0.87; 0.84; 0.87 Probability of survival

Primary: Complete Response Rate — 34 Participants

Primary: 5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD — 83 percentage of participants

Primary: Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) — 1.2 mg/kg

Primary: Effect of Rituximab on EBV(+) Tumors — 0 relapses

Primary: Participants' Response — 23; 2; 3; 1 participants

Primary: To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease. — 0 participants

Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months

Primary: ORR Assess by IRC — 76.0 percentage

Primary: Event-free Survival (EFS) Rate — 17; 20 Participants

Primary: Percentage of Patients With Positron Emission Tomography (PET) Negative Disease — 37 Participants

Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants

Primary: Second-event-free Survival — 0.91 Probability of survival

Primary: Event Free Survival Without Receiving Radiation Therapy (EFSnoRT). — 0.49 Probability of survival

Primary: Objective Response — 3; 6; 3; 2 participants

Primary: PART A: Number of Participants Who Complete of 2 Cycles of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) — 30 Participants

Primary: Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF — 0.68; 0.32 proportion of participants

Primary: Number of Participants With Grade 3-5 Adverse Events — 6 Participants

Primary: Overall Response Rate — 20.0 percentage of participants

Primary: Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent…

Primary: Objective Response Rate (ORR) — 25.00; 37.50; 75.00; 62.50 percentage of patients

Primary: Response Rate After 2 Courses of Therapy — 4 participants

Primary: Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy — 5; 5 Participants